| Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs (NCT00791895) | Novo Nordisk A/S | 2003-06-26 |
| AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus (NCT00241605) | GlaxoSmithKline | 2003-06-25 |
| Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin (NCT00082381) | AstraZeneca | 2003-06-01 |
| Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020) (NCT00543361) | Merck Sharp & Dohme LLC | 2003-05-01 |
| MK0767 and Sulfonylurea Combination Study (0767-027) (NCT00543491) | Merck Sharp & Dohme LLC | 2003-05-01 |
| A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion (NCT00238472) | Novartis Pharmaceuticals | 2003-05-01 |
| Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes (NCT00174681) | Sanofi | 2003-04-01 |
| Atorvastatin and LDL Profile in Non-Insulin Dependent Diabetes Mellitus (NCT00640549) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2003-03-01 |
| Efficacy and Safety Study of Chromium Picolinate + Biotin on Glucose and Cholesterol Control in T2DM (NCT00289354) | Nutrition 21, Inc. | 2003-03-01 |
| Pharmacodynamics and Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes (NCT01497561) | Novo Nordisk A/S | 2003-03-01 |
| Glycemic Optimization Treatment Study (NCT00552370) | Sanofi | 2003-03-01 |
| Safety and Efficacy of Insulin Detemir in Combination With OAD in Type 2 Diabetes (NCT00604396) | Novo Nordisk A/S | 2003-03-01 |
| Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes (NCT00283751) | Novo Nordisk A/S | 2003-03-01 |
| NovoLet® Surveillance Study on Using Human Insulin System in Indonesia (NCT01492153) | Novo Nordisk A/S | 2003-02-11 |
| Initiation of Insulin Aspart in Type 2 Diabetes (NCT00572806) | Novo Nordisk A/S | 2003-02-05 |
| Study A - MK0767 Monotherapy Study (NCT00543517) | Merck Sharp & Dohme LLC | 2003-02-01 |
| Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes (NCT00240422) | Boehringer Ingelheim | 2003-02-01 |
| Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes (NCT00118963) | Steno Diabetes Center Copenhagen | 2003-01-01 |
| Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST) (NCT00442845) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2003-01-01 |
| SMOOTH - Blood Pressure Control in Diabetic/Obese Patients (NCT00239538) | Boehringer Ingelheim | 2003-01-01 |
| Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (NCT00442325) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2003-01-01 |
| Placebo Controlled Metformin and Sulfonylurea Combination Study in Patients With Type 2 Diabetes (0767-025) (NCT00543751) | Merck Sharp & Dohme LLC | 2003-01-01 |
| A Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Sildenafil on the As-Needed Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes (NCT00645268) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2002-12-01 |
| Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial (NCT00110448) | Kumamoto University | 2002-12-01 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers (NCT01620463) | Novo Nordisk A/S | 2002-12-01 |
| Comparison of Glycemic Control Achieved With 2 Different Needles (NCT00572052) | Novo Nordisk A/S | 2002-12-01 |
| Prevention of Type 2 Diabetes Mellitus in Children (NCT00073268) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2002-12-01 |
| Effects of Different Mode of Exercise Training on Type 2 Diabetes (NCT01000519) | Singapore General Hospital | 2002-12-01 |
| Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes (NCT00568984) | Novo Nordisk A/S | 2002-11-21 |
| Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Japanese Subjects (NCT01527630) | Novo Nordisk A/S | 2002-11-16 |
| Lispro Mix 25 vs. Glargine in Type 2 Diabetics (NCT00551356) | Eli Lilly and Company | 2002-11-01 |
| MK0767 Glipizide Comparator Cardiac Safety Study (0767-018) (NCT00543010) | Merck Sharp & Dohme LLC | 2002-11-01 |
| Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes (NCT00111540) | AstraZeneca | 2002-11-01 |
| Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy (NCT00598793) | Novo Nordisk A/S | 2002-11-01 |
| Rosiglitazone-Induced Weight Gain (NCT00225225) | Stanford University | 2002-10-01 |
| Rosiglitazone Plaque Study (NCT00123227) | Royal Brompton & Harefield NHS Foundation Trust | 2002-10-01 |
| Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes (NCT00191282) | Eli Lilly and Company | 2002-10-01 |
| Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes (NCT00168519) | Baker Heart Research Institute | 2002-10-01 |
| Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes (NCT01720303) | Novo Nordisk A/S | 2002-09-19 |
| Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin (NCT00329225) | GlaxoSmithKline | 2002-09-01 |
| Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes (NCT01467401) | Novo Nordisk A/S | 2002-08-19 |
| Glucose/Insulin Responses:Subjects With Type 2 Diabetes Consuming Diabetes-Specific vs Standard Nutritional Formulas (NCT00540488) | Abbott Nutrition | 2002-08-01 |
| Cyber Disease Management: Using the World Wide Web to Share the Medical Record With Patients at Home (NCT00194506) | University of Washington | 2002-08-01 |
| Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes (NCT01511172) | Novo Nordisk A/S | 2002-08-01 |
| Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination (NCT00044668) | AstraZeneca | 2002-08-01 |
| Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes (NCT01720290) | Novo Nordisk A/S | 2002-07-25 |
| Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes (NCT01697631) | Novo Nordisk A/S | 2002-07-22 |
| Evaluation of the Effect of Pramlintide on Satiety and Food Intake (NCT00042601) | AstraZeneca | 2002-07-01 |
| Long-Term Effects of Sucontral(TM) on Mild and Moderate Cases of Diabetes Mellitus (Type 2) (NCT00315718) | Harras Pharma Curarina GmbH | 2002-06-01 |
| Evaluation of the Bioavailability of Pramlintide (NCT00042471) | AstraZeneca | 2002-06-01 |
| Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 in Type 2 Diabetes (NCT01487798) | Novo Nordisk A/S | 2002-06-01 |
| Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes (NCT01526980) | Novo Nordisk A/S | 2002-05-01 |
| Effect Of Rosiglitazone On Carotid Intima Media Thickness In Patients With Insulin Resistance Syndrome And/Or Type 2 Diabetes (NCT00306644) | GlaxoSmithKline | 2002-05-01 |
| Efficacy and Safety In Poorly Controlled Type 2 Diabetics (NCT00044460) | GlaxoSmithKline | 2002-05-01 |
| Dealing With Anxiety: A Cognitive Behavioural Program for Diabetes (NCT00659932) | Hunter and New England Health | 2002-05-01 |
| Efficacy of Repaglinide in Subjects With Type 2 Diabetes (NCT01698931) | Novo Nordisk A/S | 2002-04-26 |
| Variation of Genes Controlling Carbohydrate and Lipid Metabolism (NCT03310502) | Turku University Hospital | 2002-04-17 |
| Special Survey of Production of Insulin Aspart Specific Antibody (NCT01487369) | Novo Nordisk A/S | 2002-04-01 |
| Special Survey for Paediatric Subjects (NCT01487382) | Novo Nordisk A/S | 2002-04-01 |
| Special Survey for Type 1 or Type 2 Diabetic Patients (NCT01487408) | Novo Nordisk A/S | 2002-04-01 |
| Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes (NCT01465152) | Novo Nordisk A/S | 2002-03-06 |
| Safety and Efficacy of Insulin Aspart in Type 2 Diabetes (NCT01649570) | Novo Nordisk A/S | 2002-03-01 |
| The Diabetes Specialist Nurse as Delegated Main Care Provider for Patients With Type 2 Diabetes (NCT00394875) | Medical Research Foundation, The Netherlands | 2002-03-01 |
| Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin (NCT00039013) | AstraZeneca | 2002-03-01 |
| A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes Mellitus (NCT00399724) | Sanofi | 2002-03-01 |
| Konjac-Glucomannan Fibre Blend and American Ginseng in Type 2 Diabetes (NCT02806349) | Vladimir Vuksan | 2002-03-01 |
| Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Insulin in Elderly People With Type 2 Diabetes (NCT00676819) | Novo Nordisk A/S | 2002-01-10 |
| Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications (NCT00097786) | Novartis Pharmaceuticals | 2002-01-01 |
| Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients (NCT00034255) | GMP Endotherapeutics | 2001-12-01 |
| Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED) (NCT00551876) | Organon and Co | 2001-12-01 |
| Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin (NCT00384215) | Sanofi | 2001-12-01 |
| Insulin Glargine Combination Therapies in Type II Diabetics (NCT00783744) | Sanofi | 2001-12-01 |
| Noninvasive Transcutaneous Glucometer Development (NCT01168076) | InLight Solutions | 2001-12-01 |
| Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes (NCT01527539) | Novo Nordisk A/S | 2001-11-23 |
| Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes (NCT01605773) | Novo Nordisk A/S | 2001-11-08 |
| Treating Periodontal Infection: Effects on Glycemic (NCT00016835) | University of Michigan | 2001-10-17 |
| Observational Study of NovoNorm® in Subjects With Diabetes (NCT01498913) | Novo Nordisk A/S | 2001-08-30 |
| A Brief Intervention to Improve Medication Knowledge and Adherence Among Family Medicine Patients in South Texas (NCT00846300) | The University of Texas Health Science Center at San Antonio | 2001-08-01 |
| Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment (NCT01336751) | Sanofi | 2001-07-01 |
| A Study To Evaluate The Effect Of Topiramate On Clinical And Electrophysiological Parameters In Subjects With Diabetic Peripheral Polyneuropathy (NCT00231673) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2001-07-01 |
| Comparison of the Efficacy and Tolerability of the Addition of AVANDIA to Submaximal Doses of Metformin (NCT00501020) | GlaxoSmithKline | 2001-06-05 |
| Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients (NCT00174824) | Sanofi | 2001-06-01 |
| Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes (NCT01562561) | Novo Nordisk A/S | 2001-06-01 |
| Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes (NCT00145925) | The George Institute | 2001-06-01 |
| Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes (NCT01508949) | Novo Nordisk A/S | 2001-06-01 |
| Lifestyle Intervention's Impact on Health Care Costs (NCT00717158) | University of Virginia | 2001-05-01 |
| Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes (NCT01508923) | Novo Nordisk A/S | 2001-05-01 |
| A Study of the Efficacy and Safety of Topiramate in Obese, Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea Therapy (NCT00231634) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2001-05-01 |
| Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes (NCT01704378) | Novo Nordisk A/S | 2001-04-18 |
| Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes (NCT01509742) | Novo Nordisk A/S | 2001-04-01 |
| RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (NCT00379769) | GlaxoSmithKline | 2001-04-01 |
| Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet (NCT00118950) | Steno Diabetes Center Copenhagen | 2001-03-01 |
| Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent (NCT01511198) | Novo Nordisk A/S | 2001-02-01 |
| Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group (NCT01511185) | Novo Nordisk A/S | 2001-02-01 |
| Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 Diabetes (NCT01620424) | Novo Nordisk A/S | 2001-02-01 |
| A Study Looking Into the Effect of NNC 55-0414 in Subjects With Type 2 Diabetes (NCT00400283) | Novo Nordisk A/S | 2001-01-19 |
| Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes (NCT01467375) | Novo Nordisk A/S | 2001-01-08 |
| A Study of the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetes Patients on a Controlled Diet (NCT00231530) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2001-01-01 |
| Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes (NCT01650129) | Novo Nordisk A/S | 2000-12-13 |
| Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes (NCT01509755) | Novo Nordisk A/S | 2000-10-01 |